Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 108, Issue 11, Pages 4274-4280Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1016030108
Keywords
mouse model; glioma; angiogenesis; hypoxia-inducible factor 1
Categories
Funding
- American Brain Tumor Association
- National Institutes of Health [HL053670, K08CA124804, 3P30CA023100-25S8]
- National Cancer Institute [P30CA014195, R01CA132971-01A1]
- Merieux Foundation
- Ellison Medical Foundation
- Ipsen/Biomeasure
- Sanofi Aventis
- H. N. and Frances C. Berger Foundation
- James S. McDonnell Foundation
Ask authors/readers for more resources
Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti-VEGF therapy, we examined the vessels of GBMs in tumors that were induced by the transduction of p53(+/-) heterozygous mice with lentiviral vectors containing oncogenes and the marker GFP in the hippocampus of GFAP-Cre recombinase (Cre) mice. We were surprised to observe GFP(+) vascular endothelial cells (ECs). Transplantation of mouse GBM cells revealed that the tumor-derived endothelial cells (TDECs) originated from tumor-initiating cells and did not result from cell fusion of ECs and tumor cells. An in vitro differentiation assay suggested that hypoxia is an important factor in the differentiation of tumor cells to ECs and is independent of VEGF. TDEC formation was not only resistant to an anti-VEGF receptor inhibitor in mouse GBMs but it led to an increase in their frequency. A xenograft model of human GBM spheres from clinical specimens and direct clinical samples from patients with GBM also showed the presence of TDECs. We suggest that the TDEC is an important player in the resistance to anti-VEGF therapy, and hence a potential target for GBM therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available